Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Healthy controls:~* matched by age (+/- 2 years), gender and parental socioeconomic status to patients with schizophrenia.~* age between 18-55 years~* male~* physically and mentally healthy and no daily intake of medicine~* no current substance abuse~Patients:~* patients who fulfill both ICD-10 and DSM IV diagnostic criteria for schizophrenia.~* age between 18-55 years~* male~* patients who need a change in their medication~* diagnosed with schizophrenia within the last 10 years~* not formerly treated with risperidone (Risperdal) or sertindole (Serdolect) where treatment was stopped because of side effects or lack of effect~* physically healthy~* no current substance abuse~Exclusion Criteria:~Controls:~* a history of mental illness in the first degree relatives~* hearing disabilities~* head injury accompanied by unconsciousness for more than 5 min.~* physical illness with a need of daily intake of medicine~* positive screening for drugs of abuse at baseline.~Patients:~* head injury accompanied by unconsciousness for more than 5 min.~* serious medical conditions (more specific: brain diseases and diseases which cause a daily intake of medicine, heart, liver or kidney diseases, diabetes and prolongation of the QTc-interval (or a family history of such) and patients with phenylketonuri)~* abuse of alcohol or medication/ narcotics during the last 6 months or positive screening for drugs of abuse at baseline.~* former treatment with risperidone (Risperdal) or sertindole (Serdolect) where treatment was stopped because of side effects or lack of effect~* hearing disability~* allergy towards the content in the medicine used in the study~* bradycardia (pulse under 50 beats per minute) and QTc\>450 ms

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound
- 2 (Type: EXPERIMENTAL): Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound

Based on this trial design, predict the completion outcome and termination type (if applicable).